Alexion Adds More Complement System Targets to Dicerna’s RNAi-based Therapy Collaboration
Alexion Pharmaceuticals now holds exclusive rights to Dicerna’s potential RNA interference (RNAi) therapies developed against four targets of the complement system, which plays a role in many diseases, including atypical hemolytic uremic syndrome (aHUS). aHUS results from an abnormal activation of the complement system, a…